SCHEMBL7673592

SCHEMBL7673592

C[C@@H](CN1CCc2ccc(Br)cc21)NC(=O)OC(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.56
HTR2C P28335 3/20 0.56
HTR2B P41595 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
NFKB1 P19838 1/20 0.56
HIF1A Q16665 1/20 0.56
LMNA P02545 1/20 0.54
PMP22 Q01453 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
GFER P55789 1/20 0.54
AAK1 Q2M2I8 10/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CTSK P43235 3/20 0.40
CTSS P25774 2/20 0.40
CTSB P07858 2/20 0.39
NR1I3 Q14994 1/20 0.39
CTSL P07711 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673597 1.00 HTR2A (0.56) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL7677151 0.88 HDAC1 (0.43) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL7677157 0.88 HDAC1 (0.43) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL7674593 0.87 HTR2A (0.56) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL7674588 0.87 HTR2A (0.56) HTR2AHTR2CHTR2BCYP1A2CYP3A4
SCHEMBL7677943 0.84 CTSK (0.45) HDAC1HDAC6CTSKCTSSCTSB
SCHEMBL7677937 0.84 CTSK (0.45) HDAC1HDAC6CTSKCTSSCTSB
SCHEMBL1435950 0.82 LMNA (0.40) LMNAHDAC1HDAC6CTSBNR1I3
SCHEMBL7677907 0.81 CTSS (0.42) LMNACTSKCTSSCTSL
SCHEMBL7677911 0.81 CTSS (0.42) LMNACTSKCTSSCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed